Details of the Drug

General Information of Drug (ID: DMVP5YE)

Drug Name

Doxorubicin

Synonyms

doxorubicin; 23214-92-8; Doxil; Doxorubicine; Adriablastin; Doxorubicinum; 14-Hydroxydaunomycin; 14-Hydroxydaunorubicine; Doxorubicina; Adriamycin semiquinone; Doxorubicinum [INN-Latin]; Doxorubicine [INN-French]; Doxorubicina [INN-Spanish]; Myocet; FI 106; Doxorubicin [USAN:INN:BAN]; CCRIS 739; NDC 38242-874; HSDB 3070; UNII-80168379AG; NCI-C01514; EINECS 245-495-6; CHEMBL53463; CHEBI:28748; 5,12-Naphthacenedione,; ADM; ADR; ThermoDox; Aerosolized Doxorubicin; Doxorubicin citrate; RDF Rubex; Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74; DM2; JT9100000; Adiblastine (hydrochloride salt); Adr iablatina (hydrochloride salt); Adriablastine (hydrochloride salt); Adriablatina (hydrochloride salt); Adriacin (hydrochloride salt); Adriamycin PFS (TN); Adriamycin PFS (hydrochloride salt); Adriamycin RDF (TN); Adriamycin RDF (hydrochloride salt); Adriblastina (TN); Adriblastina (hydrochloride salt); Adriblatina (hydrochloride salt); Caelyx (TN); Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120; DOX-SL; Doxorubicin hydrochloride (hydrochloride salt); Doxorubicin-hLL1; Doxorubicin-hLL1 conjugate; Farmablastina (hydrochloride salt); Hydroxydaunomycin hydrochlor ide (hydrochloride salt); Hydroxydaunomycin hydrochloride (hydrochloride salt); Hydroxydaunorubicin hydrochloride (hydrochloride salt); Myocet (TN); Rubex (TN); Rubex (hydrochloride salt); TLC D-99; Doxorubicin (USAN/INN); Doxorubicin-P4/D10; Doxorubicin-P4/D10 conjugate; Cantide + adriamycin

Indication

Disease Entry	ICD 11	Status	REF
Acute myelogenous leukaemia	2A41	Approved	[1]
Adult kidney Wilms tumor	N.A.	Approved	[1]
Anterior urethra cancer	N.A.	Approved	[1]
Beckwith-Wiedemann syndrome	N.A.	Approved	[1]
Breast carcinoma	N.A.	Approved	[1]
Burkitt lymphoma	N.A.	Approved	[1]
Carcinoma	2A00-2F9Z	Approved	[1]
Childhood kidney Wilms tumor	N.A.	Approved	[1]
Epithelial ovarian cancer	2B5D	Approved	[1]
Fallopian tube neoplasm	N.A.	Approved	[1]
Hamartoma	N.A.	Approved	[1]
Hormone-resistant prostate carcinoma	N.A.	Approved	[1]
Inflammatory breast cancer	2C62	Approved	[1]
Kaposi sarcoma	2B57	Approved	[1]
Kidney neoplasm	N.A.	Approved	[1]
Leukemia	N.A.	Approved	[1]
Lung cancer	2C25.0	Approved	[1]
MALT lymphoma	N.A.	Approved	[1]
Nodal marginal zone lymphoma	2A85.0	Approved	[1]
Ovarian disorder	N.A.	Approved	[1]
Ovarian neoplasm	N.A.	Approved	[1]
Plasma cell myeloma	2A83.1	Approved	[1]
Posterior urethra cancer	N.A.	Approved	[1]
Primary systemic amyloidosis	N.A.	Approved	[1]
Small-cell lung cancer	2C25.Y	Approved	[1]
Solid tumour/cancer	2A00-2F9Z	Approved	[2]
Splenic marginal zone lymphoma	N.A.	Approved	[1]
Testicular lymphoma	N.A.	Approved	[1]
Thyroid cancer	2D10	Approved	[1]
Wilms tumor	N.A.	Approved	[1]
Hepatocellular carcinoma	2C12.02	Phase 3	[3]
Breast cancer	2C60-2C65	Phase 2	[4]
Classic Hodgkin lymphoma	N.A.	Investigative	[1]
Follicular lymphoma	2A80	Investigative	[1]
Neuroblastoma	2D11.2	Investigative	[1]
Tumour	2A00-2F9Z	Investigative	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 3

Molecular Weight (mw)

543.5

Logarithm of the Partition Coefficient (xlogp)

1.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [6]
Clearance: The drug present in the plasma can be removed from the body at the rate of 15 mL/min/kg [7]
Elimination: 3.5% of drug is excreted from urine in the unchanged form [6]
Half-life: The concentration or amount of drug in body reduced by one-half in 20 - 48 hours [7]
Metabolism: The drug is metabolized via several oxidoreductases to form a doxirubicin-semiquinone radical []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 4.47076 micromolar/kg/day [8]
Unbound Fraction: The unbound fraction of drug in plasma is 0.28% [7]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 22 L/kg [7]
Water Solubility: The ability of drug to dissolve in water is measured as 10 mg/mL [6]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Cardiotoxicity	rs7853758	SLC28A3	OT5TLTYU	[9]
Cardiotoxicity	rs17863783	UGT1A6	OTGTQ2C9	[9]
Cardiotoxicity	Not Available	TNNI2	OTGGZFSC	[10]
Cytogenetic investigations	Not Available	TOP1	OT51O0CF	[10]
Electrolyte imbalance	Not Available	BGLAP	OTK1YLWQ	[10]
Electrolyte imbalance	Not Available	PTH1R	OTQF5ZAK	[10]
Neutropenia	rs2512987	ME3	OT3XMLYG	[11]
-----------


⏷ Show the Full List of 7 ADR Information of This Drug

Chemical Identifiers

Formula: C27H29NO11
IUPAC Name: (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
Canonical SMILES: C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
InChI: InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1
InChIKey: AOJJSUZBOXZQNB-TZSSRYMLSA-N

Cross-matching ID

PubChem CID: 31703
ChEBI ID: CHEBI:28748
CAS Number: 23214-92-8
DrugBank ID: DB00997
TTD ID: D07VLY
VARIDT ID: DR00301
INTEDE ID: DR0546

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA topoisomerase II (TOP2)	TT0IHXV	TOP2A_HUMAN ; TOP2B_HUMAN	Modulator	[12]
TERT messenger RNA (TERT mRNA)	TTQY2EJ	TERT_HUMAN	Not Available	[5]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
ATP-binding cassette sub-family B member 8 (ABCB8)	DT0KQND	ABCB8_HUMAN	Substrate	[13]
ATP-binding cassette sub-family B member 5 (ABCB5)	DTKVEXO	ABCB5_HUMAN	Substrate	[14]
Fly-like putative transporter 2 (SLC22A16)	DTPATLS	S22AG_HUMAN	Substrate	[15]
Monocarboxylate transporter 1 (SLC16A1)	DT342ZG	MOT1_HUMAN	Substrate	[16]
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[17]
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[18]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[19]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[20]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[21]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[22]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[23]
Quinone reductase 1 (NQO1)	DENP5RY	NQO1_HUMAN	Substrate	[24]
Nitric oxide synthase inducible (NOS2)	DE3C1JY	NOS2_HUMAN	Substrate	[25]
Nitric oxide synthase endothelial (NOS3)	DE708H2	NOS3_HUMAN	Substrate	[25]
NADPH-cytochrome P450 reductase (CPR)_{Main DME}	DE3N2FM	NCPR_HUMAN	Substrate	[26]
Aldo-keto reductase 1C3 (AKR1C3)	DEGQTXO	AK1C3_HUMAN	Substrate	[27]
Nitric oxide synthase brain (NOS1)	DEYEK78	NOS1_HUMAN	Substrate	[25]
Aldo-keto reductase 1A1 (AKR1A1)	DED2FW3	AK1A1_HUMAN	Substrate	[28]
Xanthine dehydrogenase/oxidase (XDH)_{Main DME}	DECG04O	XDH_HUMAN	Substrate	[29]
NADH-ubiquinone oxidoreductase 30 kDa (NDUFS3)	DE741FI	NDUS3_HUMAN	Substrate	[24]
NADH-ubiquinone oxidoreductase 49 kDa (NDUFS2)	DEKX5CD	NDUS2_HUMAN	Substrate	[24]
Methionine synthase reductase (MTRR)	DE6NIY9	MTRR_HUMAN	Substrate	[30]
Succinic semialdehyde reductase (AKR7A2)	DE4G629	ARK72_HUMAN	Substrate	[31]
NADH-ubiquinone oxidoreductase 20 kDa (NDUFS7)	DEIW03B	NDUS7_HUMAN	Substrate	[24]
NADH dehydrogenase (nuoE)	DEAMEF2	J9VB37_9ACTN	Substrate	[32]
Molybdopterin-dependent enzyme (molD)	DEME01W	A0A327UAE0_9ACTN	Substrate	[33]
Molybdopterin-dependent enzyme (molD)	DEYSOD0	A0A327SQQ7_9ACTN	Substrate	[33]
Molybdopterin-dependent enzyme (molD)	DE1QMDG	A0A327U7N1_9ACTN	Substrate	[33]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
(E3-independent) E2 ubiquitin-conjugating enzyme	OTHGS2VA	UBE2O_HUMAN	Gene/Protein Processing	[34]
1,4-alpha-glucan-branching enzyme (GBE1)	OTK2N05B	GLGB_HUMAN	Gene/Protein Processing	[34]
1-acyl-sn-glycerol-3-phosphate acyltransferase delta (AGPAT4)	OT5CTQKO	PLCD_HUMAN	Gene/Protein Processing	[34]
1-acyl-sn-glycerol-3-phosphate acyltransferase gamma (AGPAT3)	OTAUR5TG	PLCC_HUMAN	Gene/Protein Processing	[34]
1-acylglycerol-3-phosphate O-acyltransferase ABHD5 (ABHD5)	OTY829Z3	ABHD5_HUMAN	Gene/Protein Processing	[34]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 (PLCB1)	OT9HYT7A	PLCB1_HUMAN	Gene/Protein Processing	[34]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-2 (PLCB2)	OTPAHDGO	PLCB2_HUMAN	Gene/Protein Processing	[34]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-3 (PLCB3)	OT0OMDEM	PLCB3_HUMAN	Gene/Protein Processing	[34]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4 (PLCB4)	OTPA0QHW	PLCB4_HUMAN	Gene/Protein Processing	[34]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-1 (PLCD1)	OT6WFVXZ	PLCD1_HUMAN	Gene/Protein Processing	[34]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Doxorubicin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Doxorubicin caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[35]
Ifosfamide	DMCT3I8	Moderate	Additive myelosuppressive effects by the combination of Doxorubicin and Ifosfamide.	Solid tumour/cancer [2A00-2F9Z]	[36]
Armodafinil	DMGB035	Minor	Increased metabolism of Doxorubicin caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[37]
LEE011	DMMX75K	Major	Decreased metabolism of Doxorubicin caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[38]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[38]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[39]
-----------


⏷ Show the Full List of 6 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Doxorubicin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Metreleptin	DM1NOEK	Moderate	Increased metabolism of Doxorubicin caused by Metreleptin mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[39]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Ivosidenib.	Acute myeloid leukaemia [2A60]	[40]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Midostaurin.	Acute myeloid leukaemia [2A60]	[38]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Idarubicin.	Acute myeloid leukaemia [2A60]	[38]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Doxorubicin caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[39]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Gilteritinib.	Acute myeloid leukaemia [2A60]	[41]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Oliceridine.	Acute pain [MG31]	[38]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Doxorubicin and Ivabradine.	Angina pectoris [BA40]	[39]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Bepridil.	Angina pectoris [BA40]	[38]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Dronedarone.	Angina pectoris [BA40]	[38]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[42]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Cilostazol.	Arterial occlusive disease [BD40]	[38]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Doxorubicin caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[39]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Doxorubicin and Levalbuterol.	Asthma [CA23]	[43]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Pirbuterol.	Asthma [CA23]	[44]
Salbutamol	DMN9CWF	Moderate	Increased risk of ventricular arrhythmias by the combination of Doxorubicin and Salbutamol.	Asthma [CA23]	[43]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Doxorubicin and Roflumilast.	Asthma [CA23]	[39]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[39]
Desipramine	DMT2FDC	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[38]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[45]
Dalfopristin	DM4LTKV	Major	Decreased metabolism of Doxorubicin caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[46]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[47]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Doxorubicin and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[38]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[45]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[45]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[45]
ABT-492	DMJFD2I	Minor	Decreased absorption of Doxorubicin due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[48]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[45]
Ag-221	DMS0ZBI	Moderate	Decreased clearance of Doxorubicin due to the transporter inhibition by Ag-221.	BCR-ABL1-negative chronic myeloid leukaemia [2A41]	[35]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Retigabine.	Behcet disease [4A62]	[38]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Doxorubicin due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[49]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Doxorubicin caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[39]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Eribulin.	Breast cancer [2C60-2C6Y]	[38]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Lapatinib.	Breast cancer [2C60-2C6Y]	[47]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Doxorubicin caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[50]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[51]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[44]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[43]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Doxorubicin and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[44]
Arformoterol	DMYM974	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[44]
Isoproterenol	DMK7MEY	Moderate	Increased risk of ventricular arrhythmias by the combination of Doxorubicin and Isoproterenol.	Conduction disorder [BC63]	[43]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Halothane.	Corneal disease [9A76-9A78]	[38]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Sevoflurane.	Corneal disease [9A76-9A78]	[38]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Probucol.	Coronary atherosclerosis [BA80]	[38]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Pasireotide.	Cushing syndrome [5A70]	[38]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Osilodrostat.	Cushing syndrome [5A70]	[39]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Doxorubicin caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[52]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Doxorubicin caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[53]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Doxorubicin caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[54]
Sertraline	DM0FB1J	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Sertraline.	Depression [6A70-6A7Z]	[38]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Doxorubicin caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[55]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Escitalopram.	Depression [6A70-6A7Z]	[38]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Clomipramine.	Depression [6A70-6A7Z]	[38]
Doxepin	DMPI98T	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Doxepin.	Depression [6A70-6A7Z]	[38]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[38]
Deutetrabenazine	DMUPFLI	Moderate	Additive CNS depression effects by the combination of Doxorubicin and Deutetrabenazine.	Dystonic disorder [8A02]	[56]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Ingrezza.	Dystonic disorder [8A02]	[57]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Doxorubicin caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[39]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Doxorubicin caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[58]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Doxorubicin caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[39]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Doxorubicin caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[39]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Doxorubicin caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[39]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Doxorubicin caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[59]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Solifenacin.	Functional bladder disorder [GC50]	[38]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Doxorubicin caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[60]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Ketoconazole.	Fungal infection [1F29-1F2F]	[38]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[38]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Doxorubicin caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[39]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Doxorubicin caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[52]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Doxorubicin caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[39]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[61]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[62]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Doxorubicin caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[39]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[38]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Doxorubicin caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[63]
Teriflunomide	DMQ2FKJ	Major	Additive myelosuppressive effects by the combination of Doxorubicin and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[64]
BMS-201038	DMQTAGO	Moderate	Decreased clearance of Doxorubicin due to the transporter inhibition by BMS-201038.	Hyper-lipoproteinaemia [5C80]	[65]
Tolvaptan	DMIWFRL	Moderate	Decreased clearance of Doxorubicin due to the transporter inhibition by Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[35]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Doxorubicin caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[66]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Doxorubicin caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[67]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Doxorubicin caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[39]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Doxorubicin and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[39]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of Doxorubicin and Denosumab.	Low bone mass disorder [FB83]	[68]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Crizotinib.	Lung cancer [2C25]	[69]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Doxorubicin caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[39]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Ceritinib.	Lung cancer [2C25]	[38]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Doxorubicin caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[52]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Doxorubicin caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[70]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Osimertinib.	Lung cancer [2C25]	[71]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Doxorubicin due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[72]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Selpercatinib.	Lung cancer [2C25]	[39]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Lumefantrine.	Malaria [1F40-1F45]	[35]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Halofantrine.	Malaria [1F40-1F45]	[73]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Hydroxychloroquine.	Malaria [1F40-1F45]	[74]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Primaquine.	Malaria [1F40-1F45]	[38]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[39]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Doxorubicin caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[75]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Doxorubicin caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[76]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[77]
Mercaptopurine	DMTM2IK	Moderate	Increased risk of hepatotoxicity by the combination of Doxorubicin and Mercaptopurine.	Mature B-cell lymphoma [2A85]	[36]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Vemurafenib.	Melanoma [2C30]	[38]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and LGX818.	Melanoma [2C30]	[78]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Doxorubicin caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[39]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Doxorubicin due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[79]
Exjade	DMHPRWG	Moderate	Increased metabolism of Doxorubicin caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[39]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Panobinostat.	Multiple myeloma [2A83]	[80]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Doxorubicin and Thalidomide.	Multiple myeloma [2A83]	[81]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Doxorubicin and Tecfidera.	Multiple sclerosis [8A40]	[82]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Doxorubicin and Siponimod.	Multiple sclerosis [8A40]	[35]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Doxorubicin and Fingolimod.	Multiple sclerosis [8A40]	[83]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Doxorubicin and Ocrelizumab.	Multiple sclerosis [8A40]	[84]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Doxorubicin and Ozanimod.	Multiple sclerosis [8A40]	[39]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Romidepsin.	Mycosis fungoides [2B01]	[38]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Doxorubicin caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[39]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Nilotinib.	Myeloproliferative neoplasm [2A20]	[38]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Dasatinib.	Myeloproliferative neoplasm [2A20]	[85]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive myelosuppressive effects by the combination of Doxorubicin and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[86]
Promethazine	DM6I5GR	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Promethazine.	Nausea/vomiting [MD90]	[38]
Rolapitant	DM8XP26	Moderate	Decreased clearance of Doxorubicin due to the transporter inhibition by Rolapitant.	Nausea/vomiting [MD90]	[87]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Entrectinib.	Non-small cell lung cancer [2C25]	[35]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Levomethadyl Acetate.	Opioid use disorder [6C43]	[39]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Lofexidine.	Opioid use disorder [6C43]	[38]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Doxorubicin caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[88]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Triclabendazole.	Parasitic worm infestation [1F90]	[38]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Pimavanserin.	Parkinsonism [8A00]	[89]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Doxorubicin caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[90]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[91]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Lefamulin.	Pneumonia [CA40]	[92]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Doxorubicin caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[93]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Degarelix.	Prostate cancer [2C82]	[39]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and ABIRATERONE.	Prostate cancer [2C82]	[39]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Doxorubicin caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[39]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Relugolix.	Prostate cancer [2C82]	[39]
Darolutamide	DMV7YFT	Moderate	Decreased clearance of Doxorubicin due to the transporter inhibition by Darolutamide.	Prostate cancer [2C82]	[94]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Bicalutamide.	Prostate cancer [2C82]	[39]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Levomepromazine.	Psychotic disorder [6A20-6A25]	[38]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Doxorubicin and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[95]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[96]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Doxorubicin and Canakinumab.	Rheumatoid arthritis [FA20]	[97]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Doxorubicin and Rilonacept.	Rheumatoid arthritis [FA20]	[97]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Doxorubicin and Golimumab.	Rheumatoid arthritis [FA20]	[98]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Doxorubicin caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[39]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Doxorubicin and Leflunomide.	Rheumatoid arthritis [FA20]	[64]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Quetiapine.	Schizophrenia [6A20]	[38]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Aripiprazole.	Schizophrenia [6A20]	[35]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Iloperidone.	Schizophrenia [6A20]	[38]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Paliperidone.	Schizophrenia [6A20]	[38]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Amisulpride.	Schizophrenia [6A20]	[99]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Asenapine.	Schizophrenia [6A20]	[38]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Pimozide.	Schizophrenia [6A20]	[39]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Doxorubicin when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[100]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Doxorubicin caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[101]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Doxorubicin caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[39]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Pitolisant.	Somnolence [MG42]	[39]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[38]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Doxorubicin caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[102]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Lenvatinib.	Thyroid cancer [2D10]	[38]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Cabozantinib.	Thyroid cancer [2D10]	[39]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Papaverine.	Tonus and reflex abnormality [MB47]	[103]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[47]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Procainamide.	Ventricular tachyarrhythmia [BC71]	[38]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Propafenone.	Ventricular tachyarrhythmia [BC71]	[38]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Flecainide.	Ventricular tachyarrhythmia [BC71]	[38]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[38]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Doxorubicin and Ganciclovir.	Virus infection [1A24-1D9Z]	[35]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Doxorubicin and Valganciclovir.	Virus infection [1A24-1D9Z]	[35]
-----------


⏷ Show the Full List of 166 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Histidine	E00106	6274	Antioxidant; Buffering agent
Hydrochloric acid	E00015	313	Acidulant
Ammonium sulfate	E00490	6097028	Buffering agent
Cholesterol	E00092	5997	Emollient; Emulsifying agent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Soybean lecithin	E00637	Not Available	Other agent
Water	E00035	962	Solvent
N-(carbonyl-methoxypolyethylene glycol 2000)-1	E00685	86278269	Other agent
--------------------


⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Doxorubicin Hydrochloride 20mg/10ml liposomaldispersion	20mg/10ml	Liposomaldispersion	Intravenous
Doxorubicin Hydrochloride 10mg/5ml solution	10mg/5ml	Solution	Intravenous
Doxorubicin Hydrochloride 20mg/10ml solution	20mg/10ml	Solution	Intravenous
Doxorubicin Hydrochloride 50mg/25ml solution	50mg/25ml	Solution	Intravenous

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Doxorubicin FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7069).
3	ClinicalTrials.gov (NCT02112656) Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC) (OPTIMA). U.S. National Institutes of Health.
4	Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. J Natl Cancer Inst. 1990 Nov 7;82(21):1706-10.
5	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
6	BDDCS applied to over 900 drugs
7	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9	Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol. 2016 Sep;82(3):683-95. doi: 10.1111/bcp.13008. Epub 2016 Jun 30.
10	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
11	Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci. 2013 Aug;104(8):1074-82. doi: 10.1111/cas.12186. Epub 2013 Jun 10.
12	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
13	ABCB8 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome. Mol Cancer Res. 2009 Jan;7(1):79-87.
14	ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005 May 15;65(10):4320-33.
15	Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010 Mar 16;102(6):1003-9.
16	Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action. Adv Drug Deliv Rev. 2010 Jul 31;62(9-10):904-17.
17	Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
18	The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
19	Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
20	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
21	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
22	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
23	Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
24	Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52.
25	The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004 Apr;18(6):664-75.
26	Kinetics of anthracycline antibiotic free radical formation and reductive glycosidase activity. Arch Biochem Biophys. 1983 May;223(1):68-75.
27	Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. Toxicol Lett. 2008 Sep;181(1):1-6.
28	Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos. 2008 Oct;36(10):2113-20.
29	Xanthine oxidoreductase in drug metabolism: beyond a role as a detoxifying enzyme. Curr Med Chem. 2016;23(35):4027-4036.
30	Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase. Biochemistry. 2002 Nov 12;41(45):13378-85.
31	Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin. J Pharmacol Exp Ther. 2010 Dec;335(3):533-45.
32	Bacterial inactivation of the anticancer drug doxorubicin. Chem Biol. 2012 Oct 26;19(10):1255-64.
33	Transformation of the anticancer drug doxorubicin in the human gut microbiome. ACS Infect Dis. 2018 Jan 12;4(1):68-76.
34	Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
35	Cerner Multum, Inc. "Australian Product Information.".
36	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
37	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
38	Canadian Pharmacists Association.
39	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
40	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
41	Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
42	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
43	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
44	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
45	Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
46	Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77. [PMID: 11103749]
47	Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
48	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
49	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
50	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
51	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
52	Product Information. Adriamycin PFS (doxorubicin). Pharmacia and Upjohn, Kalamazoo, MI.
53	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
54	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
55	Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
56	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
57	Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
58	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
59	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
60	Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
61	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
62	Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
63	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
64	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
65	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
66	Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
67	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
68	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
69	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
70	Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
71	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
72	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
73	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
74	Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
75	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
76	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
77	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
78	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
79	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
80	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
81	Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
82	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
83	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
84	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
85	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
86	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
87	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
88	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
89	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
90	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
91	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
92	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
93	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
94	Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
95	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
96	Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
97	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
98	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
99	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
100	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
101	Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
102	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
103	Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]